Daniel J. Wallace

41.5k total citations · 7 hit papers
292 papers, 16.3k citations indexed

About

Daniel J. Wallace is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel J. Wallace has authored 292 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Rheumatology, 115 papers in Immunology and 67 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel J. Wallace's work include Systemic Lupus Erythematosus Research (193 papers), Monoclonal and Polyclonal Antibodies Research (62 papers) and T-cell and B-cell Immunology (44 papers). Daniel J. Wallace is often cited by papers focused on Systemic Lupus Erythematosus Research (193 papers), Monoclonal and Polyclonal Antibodies Research (62 papers) and T-cell and B-cell Immunology (44 papers). Daniel J. Wallace collaborates with scholars based in United States, United Kingdom and Germany. Daniel J. Wallace's co-authors include Michael H. Weisman, Joan T. Merrill, Michelle Petri, Richard Furie, Ellen M. Ginzler, James R. Klinenberg, Mariana Linker‐Israeli, Kenneth Kalunian, David Isenberg and William Stohl and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Daniel J. Wallace

280 papers receiving 15.7k citations

Hit Papers

A phase III, randomized, ... 1988 2026 2000 2013 2011 2009 2005 1988 2005 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    2011 1.1k citations Richard Furie, Michelle Petri et al. Arthritis & Rheumatism profile →
  2. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
    2009 972 citations Joan T. Merrill, Daniel J. Wallace et al. Arthritis & Rheumatism profile →
  3. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
    2005 766 citations Ellen M. Ginzler, Joan T. Merrill et al. profile →
  4. Dubois' Lupus Erythematosus
    1988 560 citations Daniel J. Wallace profile →
  5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 502 citations Dafna D. Gladman, Daniel J. Wallace et al. Arthritis & Rheumatism profile →
  6. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Daniel J. Wallace, Richard Furie et al. profile →
  7. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    2023 79 citations Michelle Petri, Daniel J. Wallace et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Daniel J. Wallace 11.5k 8.4k 4.6k 1.7k 1.4k 292 16.3k
Caroline Gordon 12.5k 1.1× 8.0k 1.0× 3.4k 0.7× 2.5k 1.5× 1.2k 0.8× 305 17.3k
Andrea Doria 10.3k 0.9× 7.0k 0.8× 2.4k 0.5× 2.6k 1.5× 872 0.6× 515 17.9k
Zahir Amoura 7.3k 0.6× 6.3k 0.7× 1.3k 0.3× 1.8k 1.0× 1.4k 0.9× 424 17.6k
Naomi F. Rothfield 12.7k 1.1× 7.8k 0.9× 4.1k 0.9× 4.6k 2.7× 851 0.6× 125 19.8k
Stefano Bombardieri 6.4k 0.6× 5.1k 0.6× 1.3k 0.3× 2.8k 1.6× 1.8k 1.2× 448 16.2k
Graciela S. Alarcón 8.8k 0.8× 3.9k 0.5× 1.2k 0.3× 1.8k 1.1× 481 0.3× 320 12.5k
Eric L. Matteson 12.4k 1.1× 4.0k 0.5× 1.3k 0.3× 3.2k 1.9× 1.2k 0.9× 465 25.5k
Michelle Petri 25.7k 2.2× 16.7k 2.0× 7.3k 1.6× 3.8k 2.2× 2.2k 1.6× 534 33.5k
Robert S. Pinals 13.5k 1.2× 3.7k 0.4× 2.5k 0.5× 2.3k 1.4× 1.6k 1.1× 60 20.1k
Jane G. Schaller 23.7k 2.1× 10.5k 1.3× 5.5k 1.2× 4.5k 2.7× 2.1k 1.5× 91 33.2k

Countries citing papers authored by Daniel J. Wallace

Since Specialization
Citations

This map shows the geographic impact of Daniel J. Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Wallace more than expected).

Fields of papers citing papers by Daniel J. Wallace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Wallace. The network helps show where Daniel J. Wallace may publish in the future.

Co-authorship network of co-authors of Daniel J. Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Wallace. A scholar is included among the top collaborators of Daniel J. Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Wallace. Daniel J. Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Munroe, Melissa E., Kendra A. Young, Rufei Lu, et al.. (2025). Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity. Lupus Science & Medicine. 12(2). e001753–e001753. 1 indexed citations
2.
Singh, Jasvinder A., Larry R. Hearld, Seth A. Eisen, et al.. (2025). Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics. Lara D. Veeken. 64(8). 4631–4640.
3.
Tumurkhuu, Gantsetseg, Richard E. Moore, Lihong Huo, et al.. (2025). Loss of Tripartite Motif–Containing Protein 21 and UVB ‐Induced Systemic Inflammation by Regulating DNA ‐Sensing Pathways. Arthritis & Rheumatology. 78(1). 172–183. 2 indexed citations
4.
Pons‐Estel, Guillermo, et al.. (2025). Impact and management of warm autoimmune haemolytic anaemia associated with systemic lupus erythematosus. Autoimmunity Reviews. 24(9). 103858–103858.
5.
6.
Noaiseh, Ghaith, Jennifer K. King, Arun S. Varadhachary, et al.. (2024). Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology. Arthritis & Rheumatology. 77(4). 383–389.
7.
Cardona, Daniela Ospina, Ignasi Rodríguez‐Pintó, Núria Bonet, et al.. (2024). Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome. Lara D. Veeken. 63(10). 2897–2902. 2 indexed citations
8.
9.
Bagui, Sikha, et al.. (2023). Resampling Imbalanced Network Intrusion Datasets to Identify Rare Attacks. Future Internet. 15(4). 130–130. 7 indexed citations
10.
Skaggs, Brian J., Jennifer Grossman, Lori Sahakian, et al.. (2021). A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. ACR Open Rheumatology. 3(4). 209–220. 20 indexed citations
11.
Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations
12.
Jones, Adrian, et al.. (2019). Raynaud’s Phenomenon From PD-1 Immune Checkpoint Inhibition. JCO Oncology Practice. 16(10). 701–702. 2 indexed citations
13.
Chan, Karen K. L., Ann E. Clarke, Rosalind Ramsey‐Goldman, et al.. (2017). Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus. 27(1). 120–123. 12 indexed citations
14.
Azizoddin, Desiree R., Mariko Ishimori, Sarah R. Ormseth, et al.. (2017). Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases. 21(4). 850–858. 13 indexed citations
15.
Rossi, Edmund A., David M. Goldenberg, Rosana Michel, et al.. (2013). Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood. 122(17). 3020–3029. 88 indexed citations
16.
Wallace, Daniel J., Frédéric Houssiau, Kathryn Hobbs, et al.. (2008). Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs). Arthritis & Rheumatism. 58(9). 22 indexed citations
17.
Wallace, Daniel J.. (2008). Lupus The Essential Clinician’s Guide. 4 indexed citations
18.
Wallace, Daniel J.. (2005). The Lupus Book. 1 indexed citations
19.
Wallace, Daniel J., et al.. (2004). Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opinion on Drug Safety. 3(4). 273–278. 26 indexed citations
20.
Tsao, Betty P., Rita M. Cantor, Kenneth Kalunian, et al.. (1997). Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus.. Journal of Clinical Investigation. 99(4). 725–731. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caroline Gordon Breakdown of academic impact, for papers by Andrea Doria Breakdown of academic impact, for papers by Zahir Amoura Breakdown of academic impact, for papers by Naomi F. Rothfield Breakdown of academic impact, for papers by Stefano Bombardieri Breakdown of academic impact, for papers by Graciela S. Alarcón Breakdown of academic impact, for papers by Eric L. Matteson Breakdown of academic impact, for papers by Michelle Petri Breakdown of academic impact, for papers by Robert S. Pinals Breakdown of academic impact, for papers by Jane G. Schaller
Rankless by CCL
2026